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A B S T R A C T
Vestibular schwannomas can be treated in different ways, but for symptomatic or growing tumors, the gold
standard is surgical removal of the lesion. In order to preserve neurovascular structures, partial removal is often
performed, leaving a residual that may grow in subsequent years. To date, there is no consensus with regard to
surgical treatment of vestibular schwannoma residuals, and so this review focuses on this topic.
A structured search was performed on PubMed searching for all articles discussing vestibular schwannoma
residuals and recurrences. Only articles discussing surgical treatment were included, focusing on studies which
also examined facial nerve outcomes.
A total of 51 articles were eligible for review and these included 375 patients. Statistical analysis was per-
formed by correlating the following parameters: patients’ gender and age at first surgery, surgical approach
adopted at first and subsequent surgeries, tumor and residual size, and extent of resection (gross total, near total,
subtotal or others) at first and subsequent surgical procedures. Facial nerve function was also analyzed focusing
on its performance when correlated with the different surgical approaches. The data were analyzed by linear
regression but there were no correlations between any of the parameters chosen. There was a statistically sig-
nificant difference between the first approach used (mainly the retrosigmoid route) compared with subsequent
approaches (mainly the translabyrinthine route). In total, 8.5 % of patients needed further treatment due to
residual regrowth. Facial nerve outcome was independent of the parameters chosen.
Exclusive surgical treatment for vestibular schwannoma residuals had a very low failure rate in terms of
requiring further treatment. The approach usually chosen for second surgery was the translabyrinthine tech-
nique, and this may be explained by the location of the residual, rather than its size. The choice of a particular
surgical approach rather than another had no influence on facial nerve function. Complications rates are
comparable to Gamma Knife Radiosurgery’s as reported in the literature.
1. Introduction
Vestibular schwannomas (VS) are benign tumors arising from the
Schwann cells of the vestibular part of the VIII cranial nerve, and are
the most common cerebellopontine angle (CPA) tumor. Management of
this pathology is challenging and different therapeutic strategies are
possible on the basis of the patients’ age, performance status or symp-
toms, or on the basis of the characteristics of the tumor such as its
dimensions, mass effect on CPA structures and growth rate [1,2]. The
first choice is a wait-and-scan approach evaluating the tumor growth
rate with MRI follow-up [1]. For symptomatic or growing tumors, the
gold standard is surgical removal of the lesion. Alternatively, a radio-
therapeutic or radiosurgical treatment can be chosen. Different
microsurgical approaches have been developed: the retrosigmoid ap-
proach, the middle cranial fossa approach, the translabyrinthine ap-
proach and, more recently, the transcanal transpromontorial approach
[1]. The goal of surgery is the gross total resection of the tumor
avoiding damage to the adjacent structures of the CPA, bearing in mind
that preservation of the facial nerve (FN) is challenging and a good
outcome for the FN contributes to maintaining quality of life [1–5]. In
particular, in cases of large VS, total removal can be associated with the
risk of FN damage with subsequent paralysis [6,7]. This is why some
surgeons may choose to leave small fragments of tumor in the surgical
cavity, to reduce the risk of disruption of vascularization and, conse-
quently, to preserve FN function [3].
Tumor recurrence is reported in about 0–11 % of follow-up after
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complete surgical removal [5], but good FN outcomes (House-Brack-
mann grade I–II) [8] have been reported following NTR and STR [9].
Recurrences or residuals of VS are challenging: the growth rate is
unpredictable, and treatment is not always required. As with primary
tumors, there are different feasible approaches in the management of
residuals or recurrences: wait-and-scan, surgery, or radiosurgery [2].
Focusing on surgical treatment, there is no agreement on the gold
standard technique to approach this pathology, and the results in the
literature are equivocal. Moreover, repeat surgery for VS residuals or
recurrences seems to result in deterioration of FN function [10], but FN
outcomes are unpredictable.
Revision surgery for removal of residuals or recurrences of a
Vestibular Schwannomas is often debated and presents controversies,
because it may determine higher rates of facial nerve paralysis and of
major complications. Lots of authors, indeed, prefer the radio-
therapeutic approach in case of recurrence, thus avoiding other surgical
operations [11]. This meta-analysis aims to evaluate the characteristics
of re-interventions (e.g., chosen approach and extent of resection) for
Vestibular Schwannoma residuals or recurrences, and aims to evaluate
the real intra-operative risk rate, focusing on intra-operative and post-
operative complications rate.
2. Materials and methods
The present study was performed following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses [12].
In August 2017, a structured search was performed on PubMed
searching the terms “acoustic AND neuroma AND residual”, “vestibular
AND schwannoma AND residual”, “acoustic AND neuroma AND re-
currence”, “vestibular AND schwannoma AND recurrence”, “acoustic
AND neuroma AND regrowth”, and “vestibular AND schwannoma AND
regrowth”.
“Residual” was defined as a part of the tumor intentionally left by
the surgeon, “recurrence” was defined as new growth of the tumor after
its total resection, whereas “regrowth” was defined as an enlargement
of a fragment of tumor intentionally left in the surgical field [2,13].
By following inclusion and exclusion criteria, titles and abstracts
eligible for further review were identified. Inclusion criteria were:
English language; abstract available; original papers; articles describing
human patients; articles describing patients who underwent revision
surgery for VS. Exclusion criteria were: non-English language; full text
unavailability; laboratory studies (e.g. cadaveric and radioanatomical
studies); animal studies; reviews of the literature; studies clearly un-
related to the object of the primary research.
After an initial screening, a second analysis was performed on the
full texts of the articles identified. Papers describing surgical treatment
of VS residuals or regrowth after a previous surgical operation were
included. The following were excluded: articles not reporting clinical
cases; articles describing patients treated with radiation therapy only or
as revision treatment after one surgery; patients treated with a wait-
and-scan policy; articles reporting a neurofibromatosis 2 case series;
articles lacking clinical information.
The main information was extracted from the final set of articles
included in this review, and then summarized. In the case of different
papers published by the same authors, in which they specified that
some patients were reported in more than one paper, only articles
showing the largest case series were considered, to avoid duplication of
patient data. Data missing in one paper or in the other, were collected
by comparing those different cited articles.
Whenever available, patients’ data regarding gender, age at first
intervention, tumor size (original value, size at moment of first inter-
vention and at revision surgery), type of approach used at first inter-
vention and revision surgery, extent of resection at first intervention
and revision surgery, eventual presence of regrowth and further treat-
ments after last revision surgery, have been collected.
Tumor removal was classified in terms of the percentage of tumor
removed by resection as follows:
- gross total (GTR, no macroscopic residual of tumor);
- near-total resection (NTR removal of more than 95 % of tumor vo-
lume);
- subtotal resection (STR, removal of less than 95 % of tumor volume)
[14].
Further categories were considered if the articles mentioned other
resection extents without defining these in detail, and the same ter-
minologies were used (e.g. “partial removal”).
According to the descriptions provided by the authors, surgical
approaches were categorized (e.g. “retrosigmoid approach”). The same
kind of surgery was considered for approaches with different names but
describing the same procedure.
Data on FN function were collected, whenever available, with re-
gard to assessment before first surgery, before and after second surgery,
and at last follow-up. Function assessment was noted as described
within the articles, noting House-Brackmann’s grading system [8] when
available, or noting the description of FN function (e.g. “palsy”). In a
further categorization for statistical analysis, House-Brackmann grade I
and II, and “mild”, “numbness” and “normal” terms were considered to
be “Normal FN function”. House-Brackmann grade III and IV and
“moderate” term were considered to be “Moderate FN function”.
House-Brackmann grade V and VI and “severe” term were considered to
be “Severe FN function”. In this categorization, terms used to assess FN
function but without a clear explanation or reference to a grading
system, were considered to be unavailable data.
Intra-operative and post-operative complications were considered
and distinguished according to the moment of occurrence (during or
after first surgery, revision surgery or subsequent operations). FN dys-
function, as mentioned above, was considered separately.
Whenever reported by the authors, site of residual was noted in
order to evaluate its influence on subsequent surgical choices.
Diverse correlations between the different types of data collected
have been analyzed, as described in the “Results” section. Linear re-




The search on the PubMed database found 626 citations, and when
adjusted for duplicates, this decreased to 617 studies. The articles were
then screened on the basis of their Abstracts. Of these, 62 were dis-
carded because they were reviews and not original articles; another 274
citations were not relevant because no surgery was performed, radio-
therapy was the only treatment administered, or the study was con-
ducted on malignant tumors. A further 18 citations were not eligible
because they were conducted on animal models, cadaveric specimens,
or they only included radioanatomic or histopathologic studies.
Moreover, 115 studies were not eligible because the full text was not
available in English. The remaining 148 citations were carefully eval-
uated and the full text was examined. Out of these, 58 were excluded
because there was insufficient data about the patients, the surgical
technique, the postoperative follow-up or the surgical outcomes. In a
further 15 studies, it was not possible to characterize the different pa-
tients included in the study. A total of 21 citations were discarded be-
cause those studies included patients in which radiotherapy or gamma
knife treatments were administered before or after the surgical proce-
dure. A staged resection was planned in three studies and they were
considered to be unique procedures rather than residual tumor surgery.
Finally, a total of 51 citations were eligible as shown in a flow diagram
(Fig. 1) and were analyzed in this study.
All of the studies included were retrospective case series or case




Based on the inclusion criteria, a total of 375 patients underwent
revision surgery for residual or recurrent vestibular schwannoma. Of
these, 148 (39.5 %) were female and 103 (27.5 %) were male; gender
was not characterized in the remaining 124 (33.0 %) patients. Age data
was available in 329 (87.7 %) cases, and the average age at revision
surgery was 45.34 (15–80) years.
3.3. Tumor characteristics
The original tumor size was mentioned for 216 (57.6 %) patients.
Although the measurement units were not uniform, it was possible to
estimate tumor size with an acceptable level of bias as described: in 158
(42.1 %) patients, the maximum diameter measurement was available
(expressed in centimeters or millimeters); in 42 (11.2 %) patients, the
lesion size was characterized by a measurement interval; the median
value of the interval was considered for the analysis (i.e. for a tumor
diameter between 1 cm and 2 cm, we considered 1.5 cm as the ap-
proximate measurement for the analysis). Moreover, in another study
where the tumor size was given as a volume measurement (cm3) in 16
(4.3 %) patients, in this case, an approximation of the diameter was
obtained using ∛x of the volume. According to these methods, the
median tumor size was 3.22 cm (1–6 cm) as the maximum diameter of
the lesion. For other patients, it was not possible to extrapolate these
data.
The residual or recurrence tumor size after the first operation was
available for 124 (33.0 %) patients: in 105 (28.0 %), an accurate dia-
meter was available; in 18 (4.8 %) patients, it was described as a
measurement interval, and in 1 (0.3 %) patient, it was expressed as a
volume. The median lesion diameter, approximated as previously de-
scribed, was 2.48 cm (0.3–5 cm).
Location of the residual tumor was reported in 114/375 cases. The
internal auditory canal was involved in 70/114 cases, with extension to
the posterior cranial fossa (3/70), the petrous apex (1/70), the cere-
bellum (1/70), or it was located within the fundus (3/70); no details of
nearby structures involvement were available among 62/70 cases.
Adherence to the FN was reported in 2/114 cases and basal turn of the
cochlea remnant was noted in 1/114 case. CPA was involved in 36/114
cases: in particular, 1/36 case was reported as “lateral brainstem” re-
sidual, 1/36 case involved cranial nerves, and 5/36 extended to the
porus acousticus internus. Residual was adherent to cerebellum in 1/
114 case. One case (1/114) was defined as a residual on the VIII cranial
nerve stump. Finally, 3/114 cases of multifocal residuals were reported.
Fig. 1. Study selection.
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3.4. First surgery
The first approach technique was a retrosigmoid approach in 236
(62.9 %) patients, a translabyrinthine approach in 48 (12.8 %) patients
(in one case, an enlarged translabyrinthine approach was performed), a
retrosigmoid combined with a translabyrinthine approach in 1 (0.3 %)
patient, a craniotomic approach not otherwise described in 3 (1%)
patients, a transotic approach in 1 (0.3 %) case, and a middle cranial
fossa approach in 1 (0.3 %) patient. In 85 (22.7 %) patients, the first
surgical technique was not described (Fig. 2).
The radicality of resection was classified as gross total in 109 (29.0
%), near-total in 16 (4.3 %), subtotal in 114 (30.4 %), intracapsular in
26 (6.9 %) and partial removal in 7 (1.9 %) patients. In 103 (27.5 %)
cases, the extent of resection was not described in the study (Fig. 3).
There was no statistical correlation between tumor size and the
surgical technique chosen in the first surgical approach (p-
value=0.1492), or between tumor size and the radicality of the first
resection (p-value=2.326).
3.5. Revision surgery
In revision surgery, the approach chosen for residual and recurrent
tumor treatment was a retrosigmoid approach in 84 (22.4 %) patients
(in seven patients, a first revision surgery via a retrosigmoid approach
was followed by a second revision surgery performed via a transla-
byrinthine approach; in one patient, two revision surgical procedures
via a retrosigmoid approach were followed by surgery by a transla-
byrinthine approach); a translabyrinthine approach in 140 (37.3 %)
patients (in 16 patients, an enlarged translabyrinthine approach was
performed; in two patients, a first revision surgery via a translabyr-
inthine approach was followed by a second surgical procedure by a
retrosigmoid approach; in three patients, two revision surgical proce-
dures were performed by a translabyrinthine approach; in six patients, a
first revision surgery by a translabyrinthine approach was followed by a
second translabyrinthine approach and a third procedure by a retro-
sigmoid approach); a modified extended middle cranial fossa approach
in 18 (4.8 %) patients (in one case, a classic middle cranial fossa ap-
proach was performed); an exploratory craniotomy in 2 (0.6 %) pa-
tients (in one of these, the craniotomy was combined with an infra-
temporal approach type A); a transotic approach in 3 (0.8 %) patients
and a transcochlear approach in 6 (1.6 %) patients. Data for 122 (32.5
%) patients were not available (Fig. 4).
By considering retrosigmoid and translabyrinthine approaches, a
statistically significant difference emerged between the technique used
Fig. 2. First surgical approach.
Fig. 3. Radicality of resection after the first surgery.
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in the first surgery and the technique used in the revision surgery (p-
value<0.00001).
The radicality of resection after revision surgery was classified as:
gross total in 141 (37.6 %); near-total in 14 (3.7 %) (three of these had
a second revision surgery obtaining a near-total, gross total, and partial
resection); subtotal in 37 (9.9 %) patients (four patients had a second
revision surgery obtaining a gross total, a subtotal and in two cases, a
near-total resection; of this last group, one patient underwent a third
revision surgery obtaining a gross total removal of the tumor); partial in
3 (0.8 %) patients (one patient had three revision surgical procedures,
all with subtotal removal of the lesion). In 180 (48.0 %) cases, the
extent of resection was not described in the study. The radicality of
revision surgery was independent of the residual/recurrent tumor size
(p-value: 0.3888) (Fig. 5).
In the articles included in the present study, the site of residual
tumor was not indicated by the authors in 261/375 patients, in 71/375
it was located in the IAC or extended to petrous apex, in 36/375 in the
CPA or adherent to the cerebellum, in 4/375 it was adherent to the VII
cranial nerve (not specified site), and in 3/375 a multifocal residual was
found.
The retrosigmoid approach tended to be used more often for the first
surgery whereas the translabyrinthine approach was used more often to
treat residuals and the difference was statistically significant (p-
value< 0.00001).
3.6. Facial nerve function
In 21 out of 51 studies, facial nerve function was described and
characterized for each patient with a total of 205 cases. Facial nerve
function was evaluated in the different studies using different classifi-
cations. In order to summarize and to standardize the results, we di-
vided facial nerve function into three groups: normal or near-normal
(corresponding to grade I or II of the House-Brackmann classification),
moderate facial palsy (corresponding to grade III or IV of the House-
Brackmann classification), and severe or complete facial palsy (corre-
sponding to grade V or VI of the House-Brackmann classification).
After the first surgical procedure, 107 (52.2 %) patients presented a
normal or near-normal facial function, 43 (21.0 %) patients presented a
Fig. 4. Surgical approach in the revision surgery.
Fig. 5. Radicality of resection after the revision surgery.
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moderate facial nerve palsy, and 55 (26.8 %) had a severe or complete
facial palsy. After the revision surgery, facial nerve function was normal
or near-normal in 73 (35.6 %) patients, moderate in 64 (31.2 %) pa-
tients, and a severe or complete facial palsy was found in 68 (33.2 %)
patients (Fig. 6).
Evaluating the difference in facial nerve function before and after
revision surgery, in 18 (8.8 %) patients, there was an improvement in
facial nerve function (from moderate to normal in four patients and
from severe to moderate in 14) in 123 (60.0 %) patients, facial nerve
function remained the same as before surgery, and in 68 (33.2 %) pa-
tients, it worsened (from normal facial function to moderate facial palsy
in 35, from moderate to severe in 20 patients, and from normal to se-
vere or complete facial palsy in 13 patients) (Table 1).
Facial nerve function after revision surgery was significantly poorer
than after the first operation (Chi-squared test: p-value=0.002705).
Regarding the correlation between modification of facial nerve
function before and after revision surgery and (1) the approach chosen
for revision surgery, (2) residual or recurrent tumor size, (3) radicality
of revision resection, and (4) approach for revision surgery corrected
for residual/recurrence tumor size and radicality of revision surgery,
none of these correlations were statistically significant, as summarized
in Table 2.
Regarding revision surgery, by considering only translabyrinthine
resections, 102 cases were performed by ENT surgeons alone, 4 by
neurosurgeons alone, while 34 cases were treated by a multidisciplinary
team (neurosurgeon and ENT). In the first subgroup, removals were
classified as 39 GTR, 4 NTR, 7 STR and 1 partial (data were not
available in 51 cases). FN function resulted to be normal in 18/102
cases, moderate in 25/102, and severe in 31/102, while data were
unavailable in 28/102 cases. The second subgroup was composed by 4
GTR and FN function resulted HB grade II in 1 case and grade III in 3
cases. In the latter subgroup there were 17 GTR, 4 NTR and 11 STR
(data were unavailable in 2 cases); FN outcome after revision surgery
resulted to be normal in 8/34 patients, moderate in 9/34, and severe in
2/34 (data were unavailable in 15/34 cases). Final regrowth occurred
in 1 case belonging to the first and 1 belonging to the third subgroup,
respectively, and both tumors had been previously subtotally removed.
3.7. Long-term results
Twelve patients who developed a recurrence or had a residual
tumor after revision surgery underwent radiotherapy (in 3 cases gamma
knife radiosurgery and in 9 cases traditional radiotherapy). Moreover, 4
patients received radiotherapy after 2 revision surgical procedures with
tumor relapse.
3.8. Complications
Regarding first surgery, post-operative course was described in 39/
375 cases. Complications did not occur during first surgery or in the
first postoperative period in 26/39 (66.6 %) patients. Complications
were described among 13 (33.3 %) patients. In 4/39 patients CSF
leakage and in 2/39 hydrocephalus were observed, 3/39 patients ex-
perienced cranial nerves lesions (IV, V, IX, X or XII cranial nerve), 1/39
patient experienced vocal chord paralysis, and 1/39 temporary dys-
phagia. At last, 1/39 suffered from multiple air embolism and 1/39
from change of vital signs. Data were not indicated by the authors in
336/375 (89.6 %) patients.
During revision surgery or in the second postoperative period,
complications were absent among 78/375 (20.8 %) patents, while they
were present in 36/375 (9.6 %). CSF alone or associated with other
symptoms occurred among 12/114 patients, while hydrocephalus was
reported among 2/114 patients. Seven patients suffered from cranial
nerve dysfunction (III-XI cranial nerves, in different associations) and in
Fig. 6. Facial nerve function after the first operation and after revision surgery.
Table 1
Modification of facial nerve function before and after the revision surgery.
Facial nerve function
Severe to normal Severe to moderate No variation Moderate to severe Normal to moderate Normal to severe
No. of patients (%) 4 (1.9 %) 14 (6.8 %) 123 (60.0 %) 20 (9.7 %) 35 (17.1 %) 13 (6.3 %)
Table 2
Statistical significance of correlations between facial nerve function before and
after revision surgery and the parameters of revision surgery.
Parameter of revision surgery p-value
Approach for revision surgery 0.05399
Residual/recurrence tumor size 0.2139
Radicality of revision surgery 0.2999
Approach for revision surgery corrected for residual/recurrence tumor
size and radicality of revision surgery
0.2818
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one of them a post-operative tracheostomy for dyspnea was needed.
Moreover, one patient suffered from corneal clouding. Ataxia occurred
in 4/114 cases, a temporary hemiparesis was present in 1/114 case,
intracranial hematoma alone was observed in 1/114 case, and me-
ningitis was present in 1/114 case. One patient experienced cardio-
vascular accident, 4 suffered from vertigo, and in 1 case hematoma of
the leg in the site of muscle grafting occurred. At last, 1 patient died
during follow-up. Data were not available in 261/375 (69.6 %) cases.
Further complications were evaluated in patients who underwent
more than 2 surgeries. Among them, no complications occurred in 18
(29 %) cases, whereas they were present in 5 (8.1 %). Cranial nerve
dysfunction was present in 2 cases and 1 of them subsequently died due
to dysphagia, ab ingestis and septic shock. CSF leakage was present in 1
case, temporary apraxia in 1, and cardiovascular accident occurred in 1
patient. Data were not present among 39/62 (62.9 %) cases.
4. Discussion
4.1. Surgical outcomes
According to some authors, after subtotal resection, VS residuals do
not show any growth for years [15–19] even though recurrence rates
after subtotal resection have been reported to be about 20 % [7,18,19].
Treatment for residual VS can be by different modalities (a wait-
and-scan policy, radiation therapy, or revision surgery) and depends on
the status of the lesion, general clinical condition and the preference
expressed by the patient [20]. In the case of a large VS encountered at
first operation, some authors have also emphasized the importance of
surgical treatment followed by adjuvant radiosurgery, to preserve
neural structures [18]. To date, to the best of our knowledge, there is no
protocol or consensus regarding the treatment of choice for VS re-
siduals, for several reasons, e.g. tumor size, patients’ age, surgeon’s
expertise, etc.
Even when gross total resection (GTR) is performed, an eventual
recurrence should not be excluded. Indeed,< 10 % recurrence rates
occurring after complete resection are reported, even though many
studies are limited by a short follow-up or low definition imaging [21].
In the present study, among the 375 cases analyzed, only 109 (29.1 %)
originally underwent GTR. This may be explained by the progressive
improvement in imaging, in particular MRI, so that earlier diagnosis
can now be made before the tumor has reached a large size; however, it
must also be considered that a significant amount of data were lacking
in this study, since there were no data regarding resection extent in 103
(27.5 %) patients.
Moreover, considering the slow growth of VS, an adequate follow-
up period is required. Nakatomi et al. [21] hypothesized a gross un-
derestimation of recurrence frequency among studies with a short
follow-up (< 5–10 years). Also, in their case series, they found a shorter
interval between treatment and recurrence among patients with sub-
total resection (STR) compared with GTR, probably due to the more
difficult detectability of a smaller VS remnant on imaging. In our meta-
analysis, the follow-up period was rarely mentioned in the selected
articles and it was not always clear whether the period started from the
first operation or the last one. Overall, on average, the follow-up period
lasted for 64.8 months, and data were not mentioned in 56 cases.
Nevertheless, since there was a wide heterogeneity and missing data, a
valid statistical analysis could not be performed.
Nakatomi et al. [21] also mentioned the importance of an adequate
follow-up period according to the type of resection of the original
tumor. They suggested an MRI scan after 2, 7 and 10 years in GTR if no
suspicious enhancement was revealed after removal, otherwise, if a
resection less than GTR was performed, more frequent MRIs are re-
commended. This prompted us to consider the higher recurrence rate
after near-total resection (NTR), STR or other partial removal. To
confirm this, among our cases analyzed, 163/375 underwent in-
complete removal. If we exclude cases with data not reported (103/
375, 27.5 %), the results show that recurrence was higher in the non-
GTR group (59.6 %) compared with the GTR group (40.4 %).
Regarding the surgical approach, the one mainly chosen at the time
of first operation was the retrosigmoid approach (236/375), and the
second was the translabyrinthine approach (48/375) with some var-
iants (1 enlarged translabyrinthine and 1 combined translabyrinthine-
retrosigmoid approach). Treatment of residuals was mainly accom-
plished with the translabyrinthine (140/375 cases) and retrosigmoid
techniques (84/375). The choice of one approach rather than the other
is dictated by different reasons, such as location of the residual, sur-
geon’s expertise and patient’s hearing status. In particular, according to
our results, the latter seemed not to be the main reason. Indeed, by
comparing hearing status between patients who underwent revision
surgery via translabyrinthine and retrosigmoid approach, data were
available among 93 patients. Among them, 69/93 had underwent a
translabyrinthine approach as first surgery, so at revision they had no
residual hearing on the affected side. The remaining 24 cases under-
went revision surgery with retrosigmoid approach (3/24) and with
translabyrinthine approach (21/24). There were no substantial differ-
ences regarding hearing status, since all of them suffered from highly
compromised hearing (as defined as “profound hearing loss”, “class C/
D”, “<50 dB PTA”, “deafness”, or “hearing loss” without further de-
tails).
In the articles included in the present study, the site of residual
tumor was not indicated by the authors in 261 patients. Therefore, since
this fundamental data was lacking for the large majority of patients, it
was not possible to correlate the residual tumor site with the chosen
approach for revision or subsequent surgeries. On the other hand, a
statistically significant difference emerged regarding the use of the
retrosigmoid and translabyrinthine techniques: the retrosigmoid ap-
proach tended to be more often used for first surgery whereas the
translabyrinthine approach was adopted to treat residuals, and this
difference was statistically significant (p-value<0.00001).
No evidence was sufficiently robust to explain the choice of a par-
ticular approach according to age, size of residual or other factors,
possibly because this case series is very heterogeneous, and perhaps it
depends on the surgeon’s choice and, in particular, on the location of
the residual, as reported in the “results” paragraph. As mentioned
above, the approach mainly chosen to treat recurrences was the
translabyrinthine approach, and this may be explained by the fact that
the residuals are generally found in the internal auditory canal. The
retrosigmoid approach allows a wide view of the cerebellopontine
angle, the possibility to resect large tumors and eventually to preserve
hearing function, but on the other hand, this approach does not provide
adequate control over tumors occurring in the internal auditory canal,
leading to the possibility of leaving tumor fragments in the surgical
cavity (even though a final check with endoscopes has been suggested
to remove any residual [22]). The disadvantages of the retrosigmoid
approach, in contrast to the ability of the translabyrinthine and the
other above-mentioned techniques to provide better control over tu-
mors in the internal auditory canal, may explain the statistically sig-
nificant choice of the latter options for revision surgery. Even if among
the selected papers there were no cases of endoscopic-assisted proce-
dures, access to the IAC during retrosigmoid approaches has been de-
scribed. Regarding first surgery drilling of the internal acoustic canal
was mentioned in 22 cases, while it was not performed or not men-
tioned in 214. Post-operative FN outcome resulted as follows: among
the IAC-drilled cases, 3/22 had severe FN function and 19/22 had no
available data; among the non-IAC-drilled patients, 84/214 had normal
FN function, 30/214 moderate, and 48/214 severe (52/214 had no
available data). Regarding revision surgery, IAC-drilled patients were
19, while non-IAC-drilled ones were 65. Post-operative FN function was
as follows: in the first subgroup, it was normal in 1/19 patient, mod-
erate in 5/19, and severe in 8/19 (no available data regarded 5/19
cases); in the second subgroup, it was normal in 18/65 cases, moderate
in 17/65, and severe in 21/65 (unavailable data regarded 11/65 cases).
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Among all patients who underwent revision surgery via retrosigmoid
approach, 15 experienced further recurrence and none of them had
been previously treated with IAC drilling.
Overall, by considering only cases with available data, after removal
of residuals, only 32/375 patients needed further treatment, re-
presenting 8.5 % of all cases. One patient (0.3 %) died during follow-up,
whereas there was no mention of further surgery or radiation therapy
among 342/375 (91.2 %) patients. Since there is no statistical corre-
lation of this result with other factors, the exclusive surgical treatment
of VS residuals has a low failure rate, independent of patients’ age, size
of the tumor and previously adopted approach, and this must be bore in
mind by the neurosurgeon or the otolaryngologist who formulates any
treatment plan.
4.2. Facial nerve outcomes
In the last few decades, management of VS has evolved significantly,
and, in particular, more attention is now paid to patients’ quality of life,
thus treatment strategies have changed [23].
Surgical treatment for VS has been proved to have good clinical
outcomes, especially in the case of small tumors [24], but quality of life
depends on multiple factors. The importance of this aspect can be in-
dicated by the presence of tinnitus, vestibular impairment or hearing
impairment [25]. In addition, FN function is considered to be the most
relevant indicator for quality of life [26]. According to Tokimura et al.
[27], continuous facial motor evoked potential monitoring may be
useful during surgical removal of VS, since this technique alerts the
surgeon to FN invasion. This aspect seems to have a predictive value on
postoperative FN outcome, so those authors underline the importance
of avoiding even transient postoperative FN dysfunction.
Each surgical approach (e.g. translabyrinthine, retrosigmoid, etc.)
has its own advantages and disadvantages, even though there is no firm
evidence to support the superiority of one over another. The same as-
sumption can also be made with regard to FN preservation: even con-
sidering subtotal resection followed by radiation treatment, there is no
definite evidence of a better outcome given by any one type of treat-
ment [28].
In a case series of 168 patients, Obaid et al. [29] compared the
translabyrinthine approach with the retrosigmoid route. According to
their analysis, resection efficacy did not show any relevant differences;
however, in terms of postoperative complications and FN preservation,
the translabyrinthine approach resulted in lower morbidity.
Good results on FN outcome were also obtained by Marchioni et al.
[30], who suggested a transcanal approach to treat small- and medium-
sized VS. In their case series, there was 95.9 % FN preservation (House-
Brackmann stage I and II), thus those results were comparable to others,
obtained with the translabyrinthine approach in two different case
series [14,31].
Small lesions can also be resected with radiation therapy: gamma-
knife radiosurgery can be used to treat VS residuals or recurrences after
microsurgical resection. In this case, there was a high rate of serviceable
FN function postoperatively, thus confirming that radiation treatment
can be a valid option [32].
To date, there are no established criteria to choose a particular
approach for VS treatment, since stereotactic radiotherapy, surgical
removal or combined approaches, and clinical observation are all well
accepted options [29]. Incomplete removals are often performed in the
case of large tumors, but in general, they are performed if there is a risk
of damage to the FN and other neurovascular structures, so a fragment
of the lesion is intentionally left in place. If this kind of resection is
performed, a near-total (> 95 %) or subtotal (< 95 %) excision is de-
fined [33] according to the percentage of tumor removed, even though
these rates vary across different studies [34]. These residuals have
different behaviors, including eventual regrowth with subsequent
compression of the surrounding structures and FN. In these cases, sur-
gical removal may be an appropriate solution, but on the other hand,
scar tissue may be a significant obstacle for the surgeon [35].
In the present study, the lack of uniformity with regard to the use of
a surgical approach may explain the high heterogeneity of our results,
not only regarding the surgical technique used, but in particular, re-
garding FN outcome. By considering FN function at the last follow-up
compared to the assessment before revision surgery, there were data for
205 patients. Among these, 18/205 cases (8.8 %) showed functional
improvement (even if this seems to be an anomalous event, since with
revision surgery a stability or a deterioration of FN function should be
expected), 62/205 (30.2 %) showed functional deterioration, and for
125/205 patients (61 %), no variation of FN function was noted. The
impact of tumor size on FN outcome has been advocated by many au-
thors, even though a wide variation in function has also been shown,
possibly due to the different methods used to assess VS size. In some
case series, there was a significant association between preoperative
tumor size and FN outcome, and in particular, FN function deteriora-
tion related to VS greater than 4 cm [36]. In our study, by comparing all
results regarding VS residuals and original tumor size, we did not find a
statistically significant correlation for FN outcome after the first op-
eration, and no differences in outcome according to the extent of re-
section.
In some cases, good results for FN function were reported, function
being improved or remaining the same after revision surgery, thanks to
intraoperative monitoring of the FN nerve itself and other possible
factors. On the other hand, in the majority of cases, FN outcome had
deteriorated. Beatty et al. [37] claimed that, for revision surgery, the
translabyrinthine approach was a safer approach than the retrosigmoid
approach, because of the possibility to approach the cerebellopontine
angle through a corridor of previously untouched tissue, thus no scars
or adhesions were present. As a result, preservation of FN function
seemed to be higher. On the other hand, according to our analysis, there
was no statistically significant correlation between FN outcome at the
last follow-up and the surgical approach chosen. Moreover, no corre-
lation was found when considering the change in FN function before
and after revision surgery.
Another matter the surgeon may have to deal with is the size of the
VS residual. Ramina et al. [35] reported a case series of patients with
large or giant VS residuals. The authors treated these large-sized lesions
with a retrosigmoid approach. FN outcomes were variable and in ac-
cordance with the overall results that we found in the literature. In our
analysis, indeed, there was no statistically significant correlation be-
tween tumor size and FN function.
The results of this study seem to show that FN functional outcome
was independent of the different factors that may have an influence on
the choice of approach by the surgeon. The choice of surgical route to
treat these residuals may be dictated by the same parameters as con-
sidered for previously untreated VS (e.g., tumor location and size, and
clinical condition of the patient). FN outcome might be influenced by
the presence of scars, by preoperative FN function and by the fact that
this is a complex operation. Further reviews might be performed to
analyze the influence of radiation therapy on FN outcome.
4.3. Complications
In the different examined articles, various kinds of complications
were noted. As reported in the “Results” paragraph, they were very
heterogeneous, thus no statistical analysis could be made. The most
frequently observed complications were CSF leakage and cranial nerve
dysfunction. There was no correspondence with a particular surgical
approach or a specific characteristic of the VS. Moreover, lots of pa-
tients were not characterized, so, for instance, it was not deducible
whether a particular complication occurred in a patient operated on
with a retrosigmoid or a translabyrinthine approach. The choice of the
surgical technique probably varied depending on surgeon’s expertise,
and this factor, together with patient and tumor characteristic, de-
termined the occurrence or not of particular complications.
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By considering only patients with available data, both with first and
second surgery, complications rate was approximately one third of
cases (33.4 % and 31.6 %, respectively), while in case of subsequent
surgeries this ratio improves to 21.9 %, maybe due to the reduced size
of VS residual to be removed. By the way, it must be bore in mind that
for the majority of patients, data on complications were not available,
so if the overall rates of complications are considered, these ones result
to be comparable to others reported in the literature regarding treat-
ment of VS residuals with Gamma Knife Radiosurgery [37,38].
4.4. Limitations of the present study
The present meta-analysis combines data from different studies to
evaluate the surgical treatment of VS residuals and to identify any
uniformity in its choice. The main limitations of this study are that the
patient population and tumor characteristics are very heterogeneous
across studies. As a result, the use of a funnel plot and test for small-
study effects, as suggested for meta-analyses, are not appropriate
[39–42], so risk assessment for bias was not performed in this study.
5. Conclusion
This study focuses on exclusive surgical treatment for vestibular
schwannoma residuals. Surgery alone, without radiosurgery or other
kinds of radiation therapy, had a very low failure rate in terms of pa-
tients requiring further treatment (8.5 %). The approach mainly chosen
for second surgery was the translabyrinthine technique, and this may be
explained by the location of the residual, rather than its size. Facial
nerve outcomes were independent of the approach chosen, tumor
characteristics, extent of resection or patient characteristics. Other
complications represent a low overall rate, which is comparable to re-
ported rates for Gamma Knife Radiosurgery. Further studies with a
different design would be necessary to show whether radiosurgery
alone had a similar or different rate of effectiveness compared with
surgery alone, as this topic goes beyond the scope of this paper.
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